Enzymatica AB (publ) (STO:ENZY)
Sweden · Delayed Price · Currency is SEK 2.580
+0.080 (3.20%)
May 6, 2026, 5:29 PM CET
Enzymatica AB Earnings Call Transcripts
Fiscal Year 2026
-
A new CEO with a strong entrepreneurial background is leading the international expansion of a scientifically validated cold treatment, ColdZyme, supported by robust clinical evidence and high customer satisfaction. The company is prioritizing partnerships and regulatory-driven market entry in Europe and beyond.
Fiscal Year 2025
-
Recent independent studies show ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, with consistent results in both human and cell models. The product was well-tolerated, and findings are expected to apply to the general population.